Optimizing long-circulating liposomes for delivery of simvastatin to C26 colon carcinoma cells

Porfire, Alina; Tomuță, Ioan; Muntean, Dana; Luca, Lavinia; Licărete, Emilia; Alupei, Marius Costel; Achim, Marcela; Vlase, Laurian; Banciu, Manuela

doi:10.3109/08982104.2014.987787

Cited by 33 publications

(30 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ratio between phospholipid concentration and drug concentration was demonstrated to have a significant impact on EE in the case of simvastatin. Thus, at high simvastatin concentration and low concentration of phospholipids, EE decreased [51].…”

Section: Drug Contentmentioning

confidence: 90%

Pharmaceutical Development of Liposomes Using the QbD Approach

Porfire¹,

Achim²,

Barbălată³

et al. 2019

Liposomes - Advances and Perspectives

Self Cite

View full text Add to dashboard Cite

Quality by Design (QbD) is a systematic, risk-based approach to pharmaceutical product and manufacturing development, which uses quality-improving scientific methods upstream in the research, development, and design phases, in order to assure that quality and safety are designed into product at as early stage as possible. This work focuses on the state-of-the-art applications of the QbD principles in the development of liposomes. The QbD approach has recently been proposed as a useful tool to obtain higher-quality liposomal products, as their development is a challenging task, involving intricate formulation and manufacturing processes. Thus, the current strategies to define the relationship between the critical material attributes or process parameters and product critical quality attributes and to establish the design space are overviewed. Additionally, the current characterization methodologies are described, as part of the control strategy required within the QbD paradigm.

show abstract

Section: Drug Contentmentioning

confidence: 90%

Pharmaceutical Development of Liposomes Using the QbD Approach

Porfire¹,

Achim²,

Barbălată³

et al. 2019

Liposomes - Advances and Perspectives

Self Cite

View full text Add to dashboard Cite

show abstract

“…The cytochrome P450 (CYP) metabolized statin, simvastatin, inhibits the adhesion of cancer cells to human mesothelial cells (HMCs) and decreases the adhesion molecules, vascular cell adhesion protein 1 (VCAM-1) on HMCs, and ICAM-1 and the cell surface receptor integrin beta 1 (integrin b1, cluster of differentiation 29, CD29) chain expression in ovarian cancer cells. This opens up the possibility of a therapeutic role for simvastatin in patients with peritoneal carcinomatosis [38] perhaps by applying long-circulating liposomes as a constant delivery system for simvastatin [39].…”

Section: Pathogenic Stimulusmentioning

confidence: 99%

Chronic inflammation evoked by pathogenic stimulus during carcinogenesis

Brücher

Jamall

2019

4open

View full text Add to dashboard Cite

A pathogenic (biological or chemical) stimulus is the earliest information received by a cell that can result in the disruption of homeostasis with consequent development of disease. Chronic inflammation involves many cell types with numerous cytokines and signaling pathways, the release of different components by the cells, and the crosstalk provoked by such stimuli involving subclinical chronic inflammation and is mechanistically manifold. Exosomes secrete chemicals that trigger the epithelium to produce exosome-like nanoparticles promoting chronic inflammation. Small molecules, together with various cytokines, selectively target signaling pathways inducing crosstalk that suppress apoptosis. 16S rRNA gene sequencing has become routine to provide information on the composition and abundance of bacteria found in human tissues and in reservoirs. The deregulation of autophagy with chronic stimulation of inflammation is an early phenomenon in carcinogenesis. The disruption of cell–cell integrity enables transcellular CagA migration and triggers deregulation of autophagy with the net result being chronic inflammation. The complex and insidious nature of chronic inflammation can be seen both inside and outside the cell and even with intracellular nuclear fragments such as chromatin, which itself can elicit a chronic inflammatory response within the cytoplasm and affect autophagy. The ultimate result of unresolved chronic inflammation is fibrosis, a step before tissue remodeling results in the formation of a precancerous niche (PCN). Various pathogenic stimuli associated with different neoplasms result in persistent inflammation. This ongoing disruption of homeostasis in the micromilieu of cells, tissues, and organs is an essential preamble to carcinogenesis and occurs early in that process.

show abstract

“…Also, the relationship between formulation factors (independent variables) and responses (dependent variables) can be further understood from these plots (19,27).…”

Section: Experimental Design Analysis Evaluation Of Variables Affectmentioning

confidence: 99%

Formulation and pharmaceutical development of quetiapine fumarate sustained release matrix tablets using a QbD approach

et al. 2017

Self Cite

View full text Add to dashboard Cite

The main objective of the present study was to apply QbD methodology in the development of once-a-day sustained release quetiapine tablets. The quality target product profile (QTPP) was defined after the pharmaceutical properties and kinetic release of the innovator product, Seroquel XR 200 mg. For the D-optimal experimental design, the level and ratio of matrix forming agents and the type of extragranular diluent were chosen as independent inputs, which represented critical formulation factors. The critical quality attributes (CQAs) studied were the cumulative percentages of quetiapine released after certain time intervals. After the analysis of the experimental design, optimal formulas and the design space were defined. Optimal formulas demonstrated zero-order release kinetics and a dissolution profile similar to the innovator product, with f 2 values of 74.53 and 83.74. It was concluded that the QbD approach allowed fast development of sustained release tablets with similar dissolution behavior as the innovator product.Keywords: quality by design, design of experiments, sustained release, hydrophilic matrix, quetiapineIn the past years, the main goal of antipsychotic drug development has been to develop molecules with higher efficacy and fewer side effects usually associated with the classic antipsychotic medications. The newly developed agents, called atypical antipsychotics, are successfully used in the treatment of both positive and negative symptoms of schizophrenia and are associated with fewer neurological and endocrine side effects compared to older medications (1). Quetiapine is a recently introduced atypical antipsychotic, which has an excellent risk/benefit ratio and is indicated as the first-line option for the treatment of psychotic disorder manifestations and schizophrenia (2). Quetiapine is available as fumarate salt in immediate as well as in sustained released formulations, the innovative product being Seroquel. The sustained release formulation was introduced several years ago and its primary objective is to release the drug slowly over an extended ALEXANDRU GAVAN

show abstract

Optimizing long-circulating liposomes for delivery of simvastatin to C26 colon carcinoma cells

Cited by 33 publications

References 30 publications

Pharmaceutical Development of Liposomes Using the QbD Approach

Pharmaceutical Development of Liposomes Using the QbD Approach

Chronic inflammation evoked by pathogenic stimulus during carcinogenesis

Formulation and pharmaceutical development of quetiapine fumarate sustained release matrix tablets using a QbD approach

Contact Info

Product

Resources

About